Medication Assistant Treatment: Evidence-Based Practice in Treating Opioid Use Disorder

Presented by:
Jason Hunt, MD
Assistant Professor
Division of Addiction Medicine
Department of Psychiatry

University of Florida

Faculty Disclosure:

Dr. Hunt has disclosed that he has no relevant financial relationships. No one else in a position to control content has any financial relationships to disclose.

Conflict of interest information for the CME Advisory Committee members can be found on the following website: All relevant financial relationships have been mitigated.

Release Date: April 13, 2022
Expiration Date:  April 12, 2025

Target Audience: All physicians

Learning Objectives:

As a result of participation in this activity, participants should be able to:

  1. Explain the need for the use of medications in the treatment of opioid use disorder.
  2. State the main medications used for the treatment of opioid addiction and better understand how they are used.
  3. Describe the use of medications for the treatment of opioid addiction among special populations including pregnant women, adolescents, pain patients, and patients with co-occurring psychiatric illness.
  4. Identify the common misconceptions about using Suboxone to treat addiction (the myths of MAT).

Requirements for successful completion: Certificates are awarded upon successful completion (80% proficiency) of the post-test.

Accreditation: The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit: The University of Florida College of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Resource(s) for further study:

  1. The Role of Science in Addressing the Opioid Crisis. Volkow, ND Collins, FS. N Engl J Med 2017; 377:391-394.
  2. A peek into opioid users’ brains as they try to quit. Lauren Neergaard, The Associated Press. Jul 13, 2019.
  3. ASAM. The Review Course in Addiction Medicine.
  4. Buprenorphine-Induced Changes in Mu-Opioid Receptor Availability in Male Heroin-Dependent Volunteers: A Preliminary Study. Zubieta et all [U Mich] Neuropsychopharmacology 23:326-334, 2000.
  5. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomized, placebo-controlled trial. Johan Kakko, Kerstin Dybrandt Svanborg, Mary Jeanne Kreek, Markus Heilig. 2003 Feb 22; 361 (9358): 662-8.
  6. Post-incarceration Fatal Overdoses After Implementing Medications for Addiction Treatment in a Statewide Correctional System. Green TC, Clarke J, Brinkley-Rubinstein L. JAMA Psychiatry. 2018; 75(4):405-407.
  7. Kampman, K et al. (2015). The ASAM National Practice Guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. Sep-Oct 2015;9(5):358-67.
  8. Association of frontal and posterior cortical gray matter volume with time to alcohol relapse: a prospective study. Rando K, Kwang-Ik H, Bhagwagar Z, Chiang-Shan R, Bergquist K, Guarnaccia J, Sinha R. Am J Psychiatry. 2011 Feb;168(2):183-92.
  9. Prelude to Passion: Limbic Activation by “Unseen” Drug and Sexual Cues. Childress, et al, PloS ONE 2008; 3(1): e1506.
  10. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. McLellan et al. JAMA. 2000 Oct 4;284(13):1689-95.
  11. Analysis of Buprenorphine/Naloxone Dosing Impact on Treatment Duration, Resource Use and Costs in the Treatment of Opioid-Dependent Adults: A Retrospective Study of US Public and Private Health Care Claims. Khemiri A et al. Postgraduate Medicine. Vol. 126, 2014 – Issue 5. Pages 113-120. 13 Mar 2015.
  12. Loss of Dopamine Transporters in Methamphetamine Abusers Recovers with Protracted Abstinence. Volkow N, et al. Journal of Neuroscience, 1 December 2001, 21(23)9414-9418.
  13. TIP 63: Medications for Opioid Use Disorder. SAMHSA. July 2021. PEP21-02-01-002.

If you have any questions please feel free to contact Nancy Boyd at (352) 594-4298 or at